New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For TEVA;NVS From The Last 14 Days
Check below for free stories on TEVA;NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
16:07 EDTNVSAnacor announces commercial launch of KERYDIN topical solution in U.S.
Subscribe for More Information
September 17, 2014
11:01 EDTTEVAActavis drops after NY AG seeks to block Alzheimer drug switch
Subscribe for More Information
08:05 EDTTEVAEagle Pharm says Teva requests motion to dismiss Bendamustine lawsuit
Subscribe for More Information
September 16, 2014
07:31 EDTNVSEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
07:27 EDTNVSIBC Life Sciences to hold a conference
Subscribe for More Information
07:21 EDTNVSHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 12, 2014
09:01 EDTTEVATeva to present Copaxone gene expression analysis
Subscribe for More Information
08:06 EDTTEVATeva presents new clinical safety data in RRMS patients treated with Laquinimod
Teva (TEVA) and Active Biotech (ACTI) announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis, or RRMS, who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in the core studies where currently identified risks were observed within the first months of laquinimod treatment. In the pooled safety analysis, rates of adverse events, or AEs, and serious AEs were lower in the open-label extensions than in the core studies and less than three percent of patients discontinued treatment due to AEs during these extensions. Additionally, shifts to potentially significant laboratory values were considerably lower in patients exposed to at least two years of laquinimod.
08:03 EDTTEVATeva, Active Biotech present laquinimod follow-up data
Subscribe for More Information
05:18 EDTNVSNovartis announces new data confirms high efficacy of Gilenya in achieving NEDA
Novartis announced new analyses presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA, which confirmed the high efficacy of Gilenya in achieving 'no evidence of disease activity', or NEDA, in people with relapsing-remitting multiple sclerosis, or RRMS, across four key disease measures - relapses, MRI lesions, brain shrinkage and disability progression. Specifically, patients taking Gilenya had a more than four-times greater likelihood of achieving NEDA across these four key measures. NEDA is currently defined as having no relapses, MRI lesions and disability progression. These new analyses from the phase III FREEDOMS and FREEDOMS II trials reinforce the value of including brain shrinkage to the definition of NEDA. The inclusion of brain shrinkage into the NEDA definition would allow physicians to obtain a more complete assessment of a patient's disease, including the underlying damage in MS.
September 11, 2014
09:31 EDTTEVATeva announces new data from Phase IIIb GLACIER study
Subscribe for More Information
03:27 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
September 10, 2014
14:25 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
05:17 EDTNVSNovartis Gilenya data confirms reducing brain shrinkage matter for MS patients
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use